AIGH Capital Management LLC Acquires 500,000 Shares of Biodesix, Inc. (NASDAQ:BDSX)

AIGH Capital Management LLC grew its holdings in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 8.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,179,812 shares of the company's stock after purchasing an additional 500,000 shares during the period. Biodesix makes up 3.0% of AIGH Capital Management LLC's portfolio, making the stock its 13th biggest position. AIGH Capital Management LLC owned about 4.25% of Biodesix worth $9,455,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Barclays PLC boosted its position in Biodesix by 1,140.5% during the 3rd quarter. Barclays PLC now owns 23,036 shares of the company's stock worth $41,000 after acquiring an additional 21,179 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Biodesix by 17.1% during the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company's stock worth $236,000 after purchasing an additional 22,500 shares during the period. Stephens Inc. AR acquired a new stake in shares of Biodesix during the fourth quarter worth approximately $303,000. Geode Capital Management LLC grew its position in Biodesix by 50.7% during the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company's stock valued at $1,433,000 after purchasing an additional 270,724 shares in the last quarter. Finally, Perkins Capital Management Inc. increased its stake in Biodesix by 46.3% in the 4th quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company's stock valued at $1,622,000 after buying an additional 335,429 shares during the period. Institutional investors and hedge funds own 20.96% of the company's stock.

Remove Ads

Analyst Ratings Changes

Separately, William Blair restated an "outperform" rating on shares of Biodesix in a report on Tuesday, March 4th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $2.95.

Insider Buying and Selling

In other news, CEO Scott Hutton sold 83,660 shares of Biodesix stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the transaction, the chief executive officer now owns 701,947 shares of the company's stock, valued at $645,791.24. This trade represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 128,702 shares of company stock worth $118,406. 69.20% of the stock is currently owned by insiders.

Biodesix Stock Down 3.9 %

BDSX stock traded down $0.02 during trading hours on Thursday, hitting $0.60. The company's stock had a trading volume of 165,951 shares, compared to its average volume of 436,644. The stock has a 50 day moving average price of $0.87 and a two-hundred day moving average price of $1.26. Biodesix, Inc. has a 12 month low of $0.59 and a 12 month high of $2.04. The company has a market capitalization of $88.02 million, a PE ratio of -1.55 and a beta of 1.10. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30.

Biodesix (NASDAQ:BDSX - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The firm had revenue of $20.43 million for the quarter, compared to the consensus estimate of $19.92 million. On average, equities research analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current year.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.